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Abstract
Background: Rheumatoid arthritis (RA) is characterized by gradual joint destruction. Tocilizumab (TCZ) significantly
suppresses symptoms, however not all patients are protected from joint damage. We investigated whether early
measurement of specific biomarkers could predict early joint protection response to tocilizumab.
Method: Serum biomarkers (CRPM, VICM, C1M, C2M, C3M (MMP-degraded CRP, vimentin type I, II and III collagen),
CTX-I/OC (bone turnover), and CRP) were measured in 740 RA patients (the LITHE study) treated with Placebo, or 4
or 8 mg/kg TCZ. Early responders were those with ≥20 % improvement in SJC or TJC by week 16. The biomarkers'
predictability of response was investigated by AUROC and classification regression tree analysis.
Results: The best biomarker predictability for identification of TCZ responders were; baseline CTX-I/OC (AUC 0.66,
p = 0.0005) and changes in C1M (AUC 0.67, p = 0.0072), C2M (AUC 0.72, p = 0.0002), C3M (AUC 0.63, p = 0.018) and
the combination of biomarkers (AUC 0.81, p = 0.0025). Patients with high bone turnover (CTX-I/OC) and low C2M
were 6.8-fold (p = 0.003) more likely to have an early response to TCZ.
Conclusion: This enhanced pharmacodynamic (PD) response enabled identification of early responders with a
superior TCZ clinical benefit. This biomarker model may assist in the identification of TCZ responsive RA patients
and thus potentially benefit individual patients.
Trial registration: Clinicaltrials.gov: NCT00106535. JAN 2005
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that is characterized by poly-articular inflammation
manifested as swollen and tender joints, and by pain and
joint deterioration resulting in progressive joint damage,
impaired function, and disability [1, 2]. One major chal-
lenge in the treatment of RA is selecting the right treat-
ment at the right dose for the individual patient, thereby
providing an optimal balance between benefit, safety and
cost of treatment [3]. The RA population is heteroge-
neous and patients do not exhibit a linear progression of
disease; thus, there is need for effective and non-invasive
ways to monitor disease activity and progression in
individual patients. As a lack of predictive biomarkers
limits the implementation of personalized health care
(PHC), it is therefore important to identify robust
biomarkers that are predictive of response [3].
Tocilizumab (TCZ) is a humanized anti-IL-6 receptor
(IL-6R) monoclonal antibody. The effects of TCZ on
joint tissue biomarkers measured in blood have been ex-
amined in several RA clinical studies, including LITHE
[4] and RADIATE [5]. Previous studies have shown that
4 and 8 mg/kg TCZ suppress tissue turnover to a different
extent [4], corresponding with the markedly different early
response rate (i.e., American College of Rheumatology
(ACR)20 outcomes, 50 vs. 30 %) [6]. However the level of
structural protection (change in Genant-modified total
Sharp score) was comparable [7]. This indicates that there
is heterogeneity of response within each dose group and
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that some patients will experience improvements only in
disease activity but not in structural protection.
RA is affected by a persistent burden of pro-
inflammatory cytokines, such as interleukins (e.g., IL-1,
IL-6, and IL-17) and tumour necrosis factor alpha (TNFα),
which drives disease progression and activity. This leads to
activation of several signalling cascades such as janus
kinases (JAK), spleen tyrosine kinase (SYK) and mitogen-
activated protein (MAP) kinase pathways, ultimately result-
ing in the secretion of proteolytical enzymes, such as
matrix metalloproteinases (MMPs), which are the main
mediators of tissue destruction [8]. Whereas the upstream
inflammatory cytokines are fast modulating and short lived
factors, the MMPs are often long-lived and can exert their
action over an extended time period. The result is a longi-
tudinal release of tissue destruction protein fragments that
are discharged into the circulation and can be measured as
direct assessments of joint destruction and protection in
response to treatment [9]. MMP-derived fragments of type
I, type II and type III collagen are the main collagens of
joint extracellular matrix. Such fragments can be measured
by assay as C1M [10], C2M and C3M [11]. Previous find-
ings have shown that such types of biomarker are prognos-
tic for structural disease progression and markers of
efficacy in RA and other joint diseases [10–13]. Another
biomarker is CRPM, which is a degradation fragment
of C-reactive protein (CRP). The main difference between
CRPM and standard CRP is that CRPM is released from
the inflammatory tissue as a marker of chronic inflamma-
tion, whereas CRP is released from the liver as an acute
reactant [14].
Type I collagen is also the most abundant protein in
bone [15], and its degradation by cathepsin K leads to
the release of the C-terminal telopeptide of type I colla-
gen (CTX-I) [16, 17]. Increased CTX-I levels are associ-
ated with elevated levels of IL-6 in postmenopausal
women [18–20-21], and IL-6 alone activates osteoclast
and augments bone resorption. CTX-I can be measured
in both urine and serum and, decreases rapidly in
response to anti-resorptive treatment in osteoporosis (OP)
[19,21,22–26]. Bone formation can be assessed by meas-
urement of osteocalcin [23]. As bone turnover is a delicate
balance between bone resorption and bone formation, it
may be more physiologically relevant to investigate the
balance between these biomarkers, rather than asses-
sing the markers separately. Bone formation is in-
creased in postmenopausal women, which could suggest
that bone health and volume are increased. However, as
bone resorption increases at a greater rate than bone for-
mation, there is a net bone loss [24]. Thus, investigating
the balance between bone resorption and bone formation,
eliminates issues of high and low turnover patients, who
may possess similar bone balance, albeit at different bone
turnover levels. Karsdal et al. [5] indicated that the bone
turnover rather than the formation or degradation alone
may be important for the response to TCZ.
As the effective treatment of RA also requires bio-
markers that are predictive of therapeutic response, the
aim of the study was to investigate whether measure-
ment of selected blood-based tissue destruction bio-
markers, assessed in RA patients at baseline or at an
early time point post-treatment with TCZ, could be
applied as diagnostic tools for selecting patients with a
higher likelihood of response to treatment.
Methods
Study design and serum samples
The LITHE study has previously been described by
Kremer et al., Smolen et al. and Bay-Jensen et al.
[7,11,25] (clinicalTrials.gov identifier: NCT00106535).
Briefly, the study is a 2-year phase III, multicentre,
randomized, three-arm, placebo-controlled, parallel group
trial in patients with moderate to severely active RA, who
had inadequate responses to methotrexate (MTX). Patients
were randomized 1:1:1 to one of three treatment groups:
4 mg/kg or 8 mg/kg TCZ, or placebo (PBO) in combin-
ation with a stable dosage of MTX (10–25 mg/week). TCZ
and PBO were given intravenously every 4 weeks. Patients
who failed to respond to treatment during the study, ie.,
they experienced <20 % improvement from baseline in the
swollen joint count (SJC) and tender joint count (TJC) at
week 16 or later, could receive blinded rescue therapy in a
stepwise fashion between weeks 16 and 28 (see study de-
scription in paper by Kremer et al. [7,11,25]. The patients
receiving rescue treatment after week 16 were described as
early non-responders in this sub-analysis, whereas the
patients who experienced at least a 20 % improve-
ment from baseline in SJC and TJC were described as
early responders. Table 1 provide a short summary of
the patient characteristics.
The study was approved by the ethics committee at
each participating institution (the list can be found at
https://clinicaltrials.gov/ct2/show/NCT00106535/) and
was conducted according to the principles of Good Clin-
ical Practice and according to the Declaration of
Helsinki. The sub-analysis of this study was done on
anonymized data, and the statistical analysis plan was
approved by the projects teams at Nordic Bioscience
and Hoffmann-La Roche. All patients provided written
informed consent allowing for retrospective analysis of
the blood samples for assessment of biomarkers of joint
tissue turnover. No steering committee was used for this
study.
Sample processing
In the study protocol, the use of serum for prospective
and retrospective exploratory biomarker analysis was in-
cluded and scheduled to be collected from patients who
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provided informed written consent. The blood was col-
lected in the morning after an overnight fast for >8 hours,
at baseline, and weeks 4 and 16. All samples were ali-
quoted and stored frozen at a temperature below −70 °C
until assayed.
The biomarkers were measured at three different sites
using different aliquots. CRP was measured by the differ-
ent central laboratories associated with the study sites.
CRP was measured in all patients in the biomarker sub-
study (n = 740). MMP3, osteocalcin (OC), CTX-I and
C2M were measured by Synarc laboratory in Lyon
France. Only 676 samples of the 740 originally included
were available for measurement from the second aliquot
and the volume was not sufficient to measure all bio-
markers (e.g., n = 626 for measurement of C2M). C1M,
C3M and CRPM were measured by Nordic Bioscience
Laboratory in Roedovre, Denmark. Only 599 samples
of the 740 originally included were available for measure-
ment in the third aliquot and the volume was not
sufficient to measure all biomarkers (e.g., n = 585 for
measurement of C1M).
Biochemical marker assays
Serum levels of C1M [26], C2M [27], C3M [28] and
CRPM [14] were measured, blinded to patient identity, by
manual competitive ELISA. Briefly, for C1M and C2M,
which measure MMP-degraded type I and II collagen
fragments, respectively, Biotin-K-GSPGKDGVRG or
biotin-KPPGRDGAAG (American peptide, Sunnyvale, CA,
USA) were coated onto the streptavidin-pre-coated 96-well
plate (Roche Diagnostics, Mannheim, Germany) and left
for 30 minutes at 20 °C. After washing (PBS + 10 %
tween 20), the calibrators, controls and undiluted serum
samples were added, followed by peroxidase-conjugated
monoclonal antibody NB104-4D3 or NB44-3C1, and incu-
bated at 4 °C overnight. The sample-antibody mix was
washed off the well plate and peroxidase reaction was
visualized by 3,3′,5,5′-tetramethylbenzidine (TMB, Kem-
En-tec, Taestrup, Denmark) at 20 °C and stopped with
sulphuric acid after 15 minutes. For C3M, which measures
the MMP-derived type III collagen neo-epitope, 96-well
streptavidin-coated plates were coated with 0.4 ng/mL of
KNGETGPQGP-biotin and left for 30 minutes at 20 °C.
After washing, calibrators, controls and serum samples
(diluted 1:1 in incubation buffer) were added, followed by
peroxidase-conjugated antibody NB51-G12. The sample-
antibody mix was incubated at 20 °C for 60 minutes. TMB
was added after washing of the plates and incubated at
20 °C and stopped with sulphuric acid after 15 minutes.
CRPM measurement followed the same procedure as
C3M, however, applying a different peroxidase-conjugated
antibody (NB94-1A7) and coater (KAFVFPKESDK-biotin).
After sample/calibrator incubation, the wells were washed
and incubated with 100 μL of TMB at 20 °C for 15 minutes,
followed by the addition of 100 μL stop solution (sulphuric
acid) in each well. The colorimetric reaction was measured
at 450 nm with reference at 650 nm using the Softmax
Pro®, version 5 software (Molecular Devices, Sunnyvale,
CA, USA). The intra- and inter-assay coefficient of
variation (CV) was <8 % and <10 %, respectively, for
all assays described above.
Serum total MMP-3 was measured by a two-site
ELISA using two polyclonal antibodies raised against
human MMP-3 (Quantikine®, R&D systems, Abingdon,
UK). The intra- and inter-assay CV was <10 %. Serum
OC and CTX-I were measured by an automated multi-
plex assay (IMPACT bone chip, Roche Diagnostics, Mann-
heim, Germany) using the same antibodies as those
employed in the corresponding single marker assays
(Elecsys, Roche Diagnostics, Mannheim, Germany) [29].
Statistical analyses
No imputation was made on missing values, however, all
data points were included resulting in different numbers
of values being included in different analyses. Missing
data points were observed for most variables, including
clinical, demographic and biomarker parameters.
Summary statistics of general demographics, baseline
RA characteristics, and baseline ACR criteria demo-
graphics (Table 1) included the number of patients and
the mean and standard deviation. Changes in clinical





Age, years, SD 740 52.5 12.3
Body mass index, kg/m2 732 27.9 6.5
Disease duration, years 740 9.6 8.2
Health assessment questionnaire 676 1.5 0.6
Pain, 100 mm visual analogue scale 733 54 22
Disease activity score in 28 joints 726 6.5 0.93
Biomarker measures
C-reactive protein, mg/L 740 2.10 2.48
C1M, nmol/L 585 109 72
C2M, nmol/L 626 0.553 0.193
C3M, nmol/L 599 43.2 22.6
CRPM, nmol/L 599 17.1 8.39
Matrix metalloproteinase 3, ng/mL 676 54.3 60.5
Osteocalcin, nmol/L 671 21.7 13.6
CTX-I, nmol/L 671 0.413 0.201
CTX-I/OC ratio 671 0.023 0.0136
CIM, C2M, C3M matrix metalloproteinase-derived fragments of type I, type II and
type III collagen, CRPM degradation fragment of C-reactive protein, CTX C-
terminal telopeptide of type I collagen
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scores and biomarkers from baseline to 4 weeks were
investigated by the Wilcoxon paired rank sum test. The
primary analysis (Figs. 1 and 2) was based on the mean
percentage (+/− standard error of the mean (SEM)) relative
to the baseline measurement of the biochemical markers.
The area under the curve (AUC) for the separation
by the biomarkers between early responders and non-
responders was tested by receiver-operator characteristic
(ROC) curve analysis (Table 2). For markers with signifi-
cant and consistent associations in the primary analysis,
further associations between change in biomarker at base-
line and week 4 were investigated using a dichotomous
approach, either logistic regression or classification and
regression analysis, in which patients were categorized
according to designation of high and low levels, and
responders and non-responders, using unpruned data.
Odds ratios were calculated using these cutoff values.
All statistical analyses were performed using MedCalc
version 12.3.0. Graphing was performed using Prism
Graphpad version 5.03.
Results
Changes in biomarkers from baseline to 4 weeks in early
responders and non-responders
The 8-mg/kg-dose group was investigated first, as this
dose had the greatest effect on biomarkers. Eight serum
biomarkers were quantified and the percentage change
from baseline was investigated by comparing early non-
responders to early responders. There was no difference
in the suppression in CRP between early responders and
Fig. 1 Level of biomarker suppression in early responders (solid line) and non-responders (dotted line) in response to 8 mg/kg tocilizumab (TCZ).
Levels of (a) matrix metalloproteinase (MMP)-mediated type I collagen fragments (C1M), (b) MMP-mediated type II collagen degradation fragments
(C2M), (c) MMP-mediated type III collagen degradation fragments (C3M), and (d) total MMP-mediated C-reactive protein degradation fragments (CRPM).
Data are percentage change from baseline and mean ± standard error. Absolute values can be found in Additional file 1: Table S1
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non-responders; all patients treated with 8 mg/kg TCZ
reached normalized levels of CRP (Additional file 1:
Figure S1). In contrast, levels of serum C1M, C2M and
C2M were already significantly inhibited after 4 weeks in
early responders as compared to non-responders (p <0.01)
(Fig. 1a, b and c). Suppression of serum CRPM was slower
in early non-responders (p <0.05), but reached the level of
the responders at week 16 (Fig. 1d). Suppression of serum
MMP3 did not differ at week 4, but there was a trend
towards separation between the two groups at week 16
(Additional file 1: Figure S1). There were no significant
differences between responders and non-responders when
looking at the ratio between CTX-I and OC (Additional
file 1: Figure S1).
Fig. 2 Level of biomarker suppression in early responders (solid line) and non-responders (dotted line) in response to 4 mg/kg tocilizumab (TCZ).
Levels of (a) matrix metalloproteinase (MMP)-mediated type I collagen fragments (C1M), (b) MMP-mediated type II collagen degradation fragments
(C2M), (c) MMP-mediated type III collagen degradation fragments (C3M), and (d) total MMP-mediated C-reactive protein degradation fragments (CRPM).
Data are percentage change from baseline and mean ± standard error. Absolute values can be found in Additional file 1: Table S2
Table 2 Number of patients from each each treatment or early responder groups classified as Mode of action responders or non-
responders.
Mode of action, non-responders(n = 353) Mode of action, responders(n = 178)
Number on tocilizumab 8 mg/kg (%), n = 175 37 (7 %) 138 (26 %)
Number on tocilizumab 4 mg/kg (%), n = 175 146 (27 %) 29 (5 %)
Number on placebo (%), n = 181 170 (32 %) 11 (2 %)
Number of early responders 228 (43 %) 144 (27 %)
Number of early non-responders 125 (24 %) 34 (6 %)
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The percentage change from baseline for eight serum
biomarkers was investigated for early non-responders
and responders (Fig. 2). The suppression of biomarkers in
the responder group was less significant in the 4 mg/kg
than the 8 mg/kg treatment group (Fig. 1 vs. Fig. 2). None
of the differences observed between responders and non-
responders with the 8 mg/kg dose were replicated in the
4 mg/kg group. There was no significant change in the
biomarker levels in the placebo group (data not shown).
Identification of a mode-of-action patient subset
TCZ is a direct modulator of CRP levels as TCZ inhibits
the release of CRP from the liver. This is part of the
mode of action (MoA) of TCZ. Patients were separated
into MoA responders and non-responders: 353 of 529
patients had <75 % reduction in CRP (Table 2). A total
of 178 patients had >75 % reduction in CRP, when 138
were treated with 8 mg/kg TCZ, 29 were treated with
4 mg/kg TCZ and 11 were treated with PBO. In the
MoA responder group 228 of the 353 were early non-
responders.
Biomarker stratification of early responders and
non-responders
The MoA responder-patient subset was used to investi-
gate which biomarkers provided the best discriminative
power, by univariate testing followed by multivariate
testing. None of the biomarkers at baseline distinguished
early responders from non-responders except for base-
line CTX-I/OC, reflecting bone turnover, which signifi-
cantly separated the two groups (AUC 0.66, p = 0.0005
(Table 3)).
Four-week change in serum C1M, C2M and C3M
significantly separated responders from non-responders
with an AUC of 0.67 (p = 0.0075), 0.72 (p = 0.0002) and
0.63 (p = 0.018) (Table 3). The absolute mean values of
each of the biomarkers at baseline and at follow up can
be found in Additional file 1: Table S1.
Combining the biomarkers by logistic regression pro-
vided an AUC of 0.79 (p = 0.0003) (Table 4). This be-
came marginally better by adding age, gender, body mass
index (BMI) and disease duration into the regression
model providing an AUC of 0.81 (p = 0.0025). The best
minimum model included baseline CTX-I/OC, change
in C2M and age (AUC 0.80, p = 0.0001) (Table 4).
Classification and regression tree analysis
The combination of biomarkers was further investigated as
a predictive tool by testing them using classification and re-
gression tree analysis, including the significant biomarkers
from Table 3. In the MoA patient subset, a high CTX-I/OC
ratio at baseline (>0.024) identified 47 of the 135 early re-
sponders (purity 96 %): only 2 of 30 non-responders were
falsely selected (Fig. 3a). Of the remaining 116 patients with
a low CTX-I/ratio, 55 had change in C2M <11 % (89 % of
baseline). This node identified 49 of the early non-
responders with purity of 89 % (Fig. 3a). Overall CARTana-
lysis provided an odds ratio of 6.8 (p <0.0001).
Discussion
All RA patients do not benefit to the same extent from
the numerous RA therapies available, suggesting stratifi-
cation of patients is required [3, 30]. Although still vig-
orously debated, preliminary evidence suggests that PHC
for RA may be achievable [3]. In the current study, we
showed that in addition to the commonly used bio-
markers, CRP and MMP3, the protein fingerprint bio-
markers C1M, C2M, C3M and CRPM were significantly
suppressed at weeks 4 and 16 after treatment with TCZ,
in a dose-dependent manner with 8 mg/kg significantly
superior to the 4 mg/kg dose. In alignment with previ-
ous findings [10, 11], the patterns of suppression of
these markers were markedly different between the two
doses and between responders and non-responders. In
the current study, we investigated the end product of
tissue destruction by measuring the collagen fragments
C1M, C2M and C3M. Clearly these tissue destruction
Table 3 Area under the receiver operating characteristic curve of individual biomarker levels at baseline and change from baseline
to 4 weeks for prediction of early response (week 16)
Baseline biomarkers Change from baseline to 4 weeks
AUC Standard error 95 % CIb P value AUC Standard error 95 % CI P value
C-reactive protein 0.537 0.0611 0.461 to 0.611 Ns 0.643 0.0577 0.555 to 0.724 Ns
C1M 0.506 0.0599 0.431 to 0.581 Ns 0.674 0.0599 0.587 to 0.752 0.0072
C2M 0.526 0.0580 0.450 to 0.600 Ns 0.723 0.0551 0.639 to 0.797 0.0002
C3M 0.557 0.0541 0.481 to 0.631 Ns 0.630 0.0581 0.542 to 0.711 0.018
CRPM 0.531 0.0567 0.455 to 0.605 Ns 0.568 0.0650 0.480 to 0.654 ns
MMP3 0.622 0.0576 0.548 to 0.693 Ns 0.627 0.0623 0.540 to 0.709 ns
CTX-I/OC 0.655 0.0493 0.581 to 0.724 0.0005 0.553 0.0660 0.465 to 0.639 ns
*P value adjusted for age, gender and disease duration. AUC area under the curve, CIM, C2M, and C3M matrix metalloproteinase-derived fragments of type I, type II and
type III collagen, MMP matrix metalloproteinase, CRPM degradation fragment of C-reactive protein, CTX-I/OC C-terminal telopeptide of type I collagen/osteocalcin
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markers provided a dynamic dose and time resolution of
the pharmacodynamic (PD) effects. C1M, C2M and C3M
are all significantly suppressed by 8 mg/kg TCZ, and not
by 4 mg/kg, compared to the placebo group [11].
None of the tissue and inflammatory biomarkers measured
at baseline were predictive of response to TCZ, with the ex-
ception of bone turnover ratio, which was significantly higher
for early responders than non-responders. This suggests that
TCZ has a superior effect in patients with destabilized bone
turnover, and levels of CTX-I/OC may be used as a selection
tool for patients who may benefit from TCZ. Importantly
this is not the case for 4 mg/kg TCZ, with which baseline
levels of C1M, C3M and CRPM are associated with response
[11]. The four biomarkers of joint tissue matrix turnover,
C1M, C2M, C3M and CTX-I/OC, measured at either base-
line or at 4 weeks post treatment, were predictive of early
clinical response. Thus, RA patients, subject to IL6-R
antagonism, can potentially be stratified into responders
and non-responders as early as 4 weeks post treatment.
While it is difficult to interpret the serum levels of
pro-inflammatory cytokines and acute-phase reactants,
because of their rather acute signalling pathways, it may
be the total burden of cytokines rather than one individ-
ual cytokine that is the final driver of disease progres-
sion. Measuring end products of tissue destruction,
which are the downstream effect of the inflammatory
signals, may enable more exact monitoring of tissue
turnover [31]. As many enzymes degrade proteins at
hot-spots, this may be considered as a convergence of
signalling pathways leading to tissue turnover and re-
modelling - the final part of tissue destruction. Tissue
destruction, therefore, may be measured through specific
circulating tissue protein fragments generated by upreg-
ulated collagenolytic enzymes [9, 32], the unique end re-
sult of specific pathological events. As an example, the
major extracellular matrix (ECM) proteins of connective
tissue of the joints are type I, II and III collagen [33].
The MMP-mediated degradation of these proteins
Table 4 Logistic regression model for accessing the area under the curve (AUC) for different combinations
Including age, BMI, gender and disease duration
Variables AUC 95 % CI P value AUC 95 % CI P value*
Baseline CTX-I/OC and delta 4 weeks C1M, C2M, C3M (n = 124) 0.79 0.71 to 0.86 0.0003 0.81 0.72 to 0.87 0.0025
Baseline CTX-I/OC and delta 4 weeks C2M (and age) 0.78 0.69 to 0.85 <0.0001 0.80 0.71 to 0.86 0.0001
The first row show results of applying an enter model, where all variable were added, whereas the second row provide a backward model where all non-significant variables
were excluded (n = 124). BMI body mass index, CTX-I/OC C-terminal telopeptide of type I collagen/osteocalcin, CIM, C2M, and C3M matrix metalloproteinase-derived fragments
of type I, type II and type III collagen. * P value for the full logistic model.
Fig. 3 Classification and regression tree analysis (CART) for prediction of early responders defined as early non-responders. The odds ratio was cal-
culated using a 2 × 2 table. Each node is described by limits above the node. Blue bars and orange bars indicate numbers of early non-responders
and responders, respectively. CTX-I C-terminal telopeptide of type I collagen, OC osteocalcin, C2M matrix metalloproteinase-derived fragments of
type II collagen, BL baseline and pct percentage change from baseline to 4 weeks
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results in specific biomarkers, C1M, C2M and C3M, re-
spectively [5, 10, 26, 28, 34 ]. This may provide a more
robust and less variable biomarker approach for use as a
diagnostic or prognostic tool.
While we consider it is an overall strength of the study
that it was conducted in the context of a well-controlled
phase III clinical trial, this may also be a weakness. The
study population represents a subset of RA patients
screened and selected from the general RA population.
As such the predictive models described may apply to
RA patients with similar clinical characteristics to those
used for model training in this study, requiring the
model to be validated in independent populations or
trials. Another limitation of the study is the relatively
small sample size for generation of a predictive model,
which may lead to some model over-fitting and thus,
potential overestimation of effect size.
Conclusions
We have demonstrated the identification of TCZ re-
sponders through analysis of simple combinations of pro-
tein degradation markers. There was a significant difference
in response prediction between the 4 and 8 mg/kg doses.
MMP-mediated tissue destruction was strongly attenuated
by TCZ treatment, which suggests that over-fitting of the
dataset is less likely.
Additional file
Additional file 1 Supplementary data for Re: Arthritis Research &
Therapy: 1228461238172039 Title: Early changes in blood-based
joint tissue destruction biomarkers are predictive of response to
tocilizumab in the LITHE study. (PPTX 186 kb)
Abbreviations
ACR: American College of Rheumatology; AUC: area under the curve; CART
Classification and regression tree CIM, C2M, C3M: matrix metalloproteinase-
derived fragments of type I, type II and type III collagen; CRP: C-reactive
protein; CRPM: degradation fragment of CRP; CTX-I: C-terminal telopeptide of
type I collagen; ELISA: enzyme-linked immunosorbent assay; IL: interleukin;
JAK: janus kinase; MAP: mitogen-activated protein; MMP: matrix metalloproteinase;
MoA: mode of action; MTX: methotrexate; OC: osteocalcin; OP: osteoporosis;
PBO: placebo; PBS: phosphate-buffered saline; PD: pharmacodynamics;
PHC: personalized health care; RA: rheumatoid arthritis; ROC: receiver-operator
curve; SYK: spleen tyrosine kinase; TCZ: tocilizumab; TMB: tetramethylbenzidine;
wk: week.
Competing interests
ACBJ, ASO, IB and MAK are full-time employees at Nordic Bioscience, a privately
owned biotech company involved in the development of biomarkers. CC, ACBJ
and MAK are shareholders of Nordic Bioscience. AP was a full-time employee of
Roche Product at the time of data analysis, and currently is a full-time employee
of AstraZeneca. None of the authors declare any other conflict of interest.
Authors’ contributions
ACBJ conducted the analysis of the data and wrote the first draft of the
paper. AP collected the clinical data. MAK designed the analysis of the study,
including the choice of biomarkers and the construction of the statistical
analysis plan. ASO did the biomarker assessments. IB did the multivariate
statistical analyses. All authors participated in the discussion of the results.
All authors read and approved the manuscript.
Acknowledgements
We with like to acknowledge the technical staff at Nordic Bioscience for laboratory
support, and the Danish Research Foundation for general support of our research
especially Sabine Hoielt and Sedi Tavallaee. Furthermore we would like to thank
Dr. Thierry Sornasse and colleagues at Roche Products Ltd. for providing the study
samples. Also we would like to thank the participating patients for providing the
blood samples. We would also like to acknowledge the contribution of our friends
at Synarc laboratories in Lyon, France, for providing the C2M measurements. The
study analysis was funded by the Danish Research foundation.
Author details
1Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 207, 2730
Herlev, Denmark. 2Roche Products Ltd., Welwyn Garden City, UK. 3Present
Address: AstraZeneca UK Ltd., Cheshire, UK. 4Clinical Development, Nordic
Bioscience, Herlev, Denmark.
Received: 13 May 2015 Accepted: 29 December 2015
References
1. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of Disease:
the link between RANKL and arthritic bone disease. Nat Clin Pract
Rheumatol. 2005;1(1):47–54.
2. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al.
Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63.
3. Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C, Genant HK,
Chamberlain C, et al. Rheumatoid arthritis - A case for Personalised Health
Care? Arthritis Care Res (Hoboken). 2014;66(9):1273-80
4. Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA.
Effect of tocilizumab combined with methotrexate on circulating
biomarkers of synovium, cartilage, and bone in the LITHE study. Semin
Arthritis Rheum. 2014;43(4):470–8.
5. Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, et al. IL-6
Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis
Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy:
Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE
Study (NCT00106522). Semin Arthritis Rheum. 2012;42(2):131–9.
6. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A,
et al. IL-6 receptor inhibition with tocilizumab improves treatment
outcomes in patients with rheumatoid arthritis refractory to anti-tumour
necrosis factor biologicals: results from a 24-week multicentre randomised
placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.
7. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint
damage in rheumatoid arthritis irrespective of its anti-inflammatory effects:
disassociation of the link between inflammation and destruction. Ann
Rheum Dis. 2012;71(5):687–93.
8. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis - the
kinase inhibitors. Bull NYU Hosp Jt Dis. 2011;69(3):233–7.
9. Karsdal MA, Delvin E, Christiansen C. Protein fingerprints - relying on and
understanding the information of serological protein measurements.
Clin Biochem. 2011;44(16):1278–9.
10. Siebuhr AS, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C,
et al. Serological identification of fast progressors of structural damage with
rheumatoid arthritis. Arthritis Res Ther. 2013;15(4):R86.
11. Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA.
Effect of tocilizumab combined with methotrexate on circulating
biomarkers of synovium, cartilage, and bone in the LITHE study. Semin
Arthritis Rheum. 2014;43(4):470–8.
12. Bay-Jensen AC, Karsdal MA, Vassiliadis E, Wichuk S, Marcher-Mikkelsen K,
Lories R, et al. Circulating citrullinated vimentin fragments reflect disease
burden in ankylosing spondylitis and have prognostic capacity for
radiographic progression. Arthritis Rheum. 2013;65(4):972–80.
13. Valdes AM, Meulenbelt I, Chassaing E, Arden NK, Bierma-Zeinstra S, Hart D,
et al. Large scale meta-analysis of urinary C-terminal telopeptide, serum
cartilage oligomeric protein and matrix metalloprotease degraded type II
collagen and their role in prevalence, incidence and progression of
osteoarthritis. Osteoarthritis Cartilage. 2014;22(5):683–9.
14. Skjot-Arkil H, Schett G, Zhang C, Larsen DV, Wang Y, Zheng Q et al.
Investigation of two novel biochemical markers of inflammation, matrix
metalloproteinase and cathepsin generated fragments of C-reactive protein, in
patients with ankylosing spondylitis. Clin Exp Rheumatol. 2012;30(3):371–9.
Bay-Jensen et al. Arthritis Research & Therapy  (2016) 18:13 Page 8 of 9
15. Seeman E, Delmas PD. Bone quality–the material and structural basis of
bone strength and fragility. N Engl J Med. 2006;354(21):2250–61.
16. Garnero P, Ferreras M, Karsdal MA, NicAmhlaoibh R, Risteli J, Borel O, et al.
The type I collagen fragments ICTP and CTX reveal distinct enzymatic
pathways of bone collagen degradation. J Bone Miner Res. 2003;18(5):859–67.
17. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, et al.
Immunochemical characterization of assay for carboxyterminal telopeptide
of human type I collagen: loss of antigenicity by treatment with cathepsin
K. Bone. 2000;26(4):367–73.
18. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an
enzyme immunoassay for a new marker of bone resorption (CrossLaps):
follow-up on hormone replacement therapy and osteoporosis risk
assessment. J Clin Endocrinol Metab. 1995;80(3):864–8.
19. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al.
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies
for measurement in serum of bone-related degradation products from
C-terminal telopeptides of type I collagen. Clin Chem. 1998;44(11):2281–9.
20. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases
substantially in the years after menopause and remains increased in older
osteoporosis patients. J Bone Miner Res. 2004;19(10):1628–33.
21. Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tanko LB. An
update on biomarkers of bone turnover and their utility in biomedical
research and clinical practice. Eur J Clin Pharmacol. 2006;62(10):781–92.
22. Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere,
Collette J, et al. Bone resorption in post-menopausal women with normal and
low BMD assessed with biochemical markers specific for telopeptide derived
degradation products of collagen type I. Calcif Tissue Int. 2001;69(3):130–7.
23. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al.
Biochemical markers and the FDA Critical Path: how biomarkers may
contribute to the understanding of pathophysiology and provide unique
and necessary tools for drug development. Biomarkers. 2009;14(3):181–202.
24. Karsdal MA, Qvist P, Christiansen C, Tanko LB. Optimising antiresorptive
therapies in postmenopausal women: why do we need to give due
consideration to the degree of suppression? Drugs. 2006;66(15):1909–18.
25. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients
with inadequate responses to methotrexate: results from the double-blind
treatment phase of a randomized placebo-controlled trial of tocilizumab safety
and prevention of structural joint damage at one year. Arthritis Rheum.
2011;63(3):609–21.
26. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al. A novel
marker for assessment of liver matrix remodeling: an enzyme-linked
immunosorbent assay (ELISA) detecting a MMP generated type I collagen
neo-epitope (C1M). Biomarkers. 2011;16(7):616–28.
27. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA.
Ankylosing spondylitis is characterized by an increased turnover of several
different metalloproteinase-derived collagen species: a cross-sectional study.
Rheumatol Int. 2012;32(11):3565-72
28. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel
assay for extracellular matrix remodeling associated with liver fibrosis: An
enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically
revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10-11):899–904.
29. Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, Garnero P. New
automated multiplex assay for bone turnover markers in osteoporosis.
Clin Chem. 2008;54(9):1554–63.
30. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating
disease activity. Ann Rheum Dis. 2013;72(1):3–6.
31. Karsdal MA, Bay-Jensen AC, Leeming DJ, Henriksen K, Christiansen C.
Quantification of “end products” of tissue destruction in inflammation may
reflect convergence of cytokine and signaling pathways - implications for
modern clinical chemistry. Biomarkers. 2013;18(5):375–8.
32. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen
AC. Novel combinations of Post-Translational Modification (PTM) neo-epitopes
provide tissue-specific biochemical markers–are they the cause or the
consequence of the disease? Clin Biochem. 2010;43(10–11):793–804.
33. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of
hepatic fibrogenesis. Semin Liver Dis. 2001;21(3):351–72.
34. Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-
linked immunosorbent assay (ELISAs) for metalloproteinase derived type II
collagen neoepitope, CIIM–increased serum CIIM in subjects with severe
radiographic osteoarthritis. Clin Biochem. 2011;44(5–6):423–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bay-Jensen et al. Arthritis Research & Therapy  (2016) 18:13 Page 9 of 9
